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Rearrangement of chromosome lp in breast cancer correlates with poor
prognostic features
P.J. Hainsworthl, K.L. Raphael2, R.G. Stillwell3, R.C. Bennett' & O.M. Garson2
University ofMelbourne Departments of'Surgery and 2Medicine and 3Department ofPathology, St. Vincent's Hospital,
Melbourne, Victoria, Australia.
Summary In a cytogenetic study of breast cancer biopsies, clonal abnormalities of chromosome lp were
identified in 56% (14) of 25 informative patients. Translocations predominated, involving lp22 (n = 1), lp35
(n = 1) or lp36 (n= 10) breakpoints. Chromosome lp abnormalities were associated with estrogen receptor
(ER) negativity (P= 0.03, 2-tailed Fisher Exact Probability test), high histological grade (P = 0.02, 2-tailed
Mann-Whitney U-test) and an unfavourable Melbourne Prognostic Score (NEPA P = 0.02, SEPA P = 0.04,
2-tailed Mann-Whitney U-tests). These findings are consistent with the possibility that a gene located on
chromosome lp is implicated in tumour progression.
Whilst cytogenetic studies in the haematological malignancies
have proved to be invaluable in both research and patient
management, the same cannot be said for the common solid
tumours. However, the finding that a locus on chromosome
5q appears to be involved in colon cancer, at least in patients
with familial polyposis coli (Bodmer et al., 1987; Solomon et
al., 1987) is important, since the initial lead for this investiga-
tion was the cytogenetic observation of a chromosome 5q
deletion in a single patient with Gardner's syndrome (Her-
rera, 1986).
One of the problems with the cytogenetic study of breast
cancer is the morass of complex chromosomal changes which
have been repeatedly described (for review see Hainsworth &
Garson, 1990) which is in sharp contrast to the single
chromosome events often seen in the leukaemias. A possible
approach towards defining those events which are important
in tumour progression is to look for chromosomal changes
which correlate with a poor prognosis.
In the course of studying breast cancer karyotypes (Hains-
worth et al., 1991) two chromosomes appeared to be of
importance. The 'earliest' change observed, based on its
occurrence in 'operable' tumours with diploid-range karyo-
types, was translocation or deletion of the long arm of
chromosome #16 involving a 16q22 breakpoint. However,
the most frequently observed rearrangements involved the
short arm of chromosome #1, which form the basis of this
report.
Materials and methods
Surgical biopsy specimens (n = 144) were received from 143
patients with primary breast cancer, one of whom had
bilateral tumours, treated between April 1987 and March
1989. Of the 144 specimens, banded analyses were possible in
31 (22%). In five cases, both normal and abnormal meta-
phases were observed but only the normal metaphases could
be karyotyped. Thus, meaningful karyotypes were obtained
in 26 patients. In the remaining 113 cases, insufficient
metaphases were obtained to enable analysis.
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Cytogenetic analysis
Cytogenetic data were obtained using a direct technique
(n = 24), synchronised short-term culture (n = 1) or both
techniques (n = 1). Full details of the methodology have been
published elsewhere (Hainsworth et al., 1991). Briefly, fresh
macroscopic tumour was transported to the laboratory in
RPMI 1640 medium (Commonwealth Serum Laboratories,
Melbourne) containing penicillin and streptomycin and
mechanically disaggregated using scalpels.
In the direct technique (Mark, 1975) 1 ml of single cell
suspension was incubated with 5 ml 0.075 M potassium
chloride and colcemid (final concentration 1.6 to 4.0pgml-')
at 37°C for 30 min. The cells were fixed in methanol/acetic
acid (3:1) and conventional air-dried slides prepared. If
Giemsa stained slides demonstrated the presence of meta-
phases further slides aged at 60°C were G-banded (Seabright,
1971). Metaphases were photographed under oil-immersion
using 50 ASA monochrome film.
In three cases a modified synchronised culture technique
was used (Webber & Garson, 1983).
Interpretation andanalysis
The International System for Human Cytogenetic Nomencla-
ture was used throughout (ISCN, 1985). Because of the
complex chromosomal changes seen, it was unusual for more
than one cell to have exactly the same karyotype. Never-
theless, particular chromosomal abnormalities were fre-
quently present in the majority of cells analysed. Structural
changes affecting two or more cells were considered clonal,
whereas losses were considered clonal only if a chromosome
was missing from at least three cells in which all remaining
chromosome were identifiable. No attempt was made to
characterise chromosomal gains.
Associations between chromosome lp abnormalities and
several staging and prognostic factors were sought. The para-
meters investigated were age, tumour size, nodal status, joint
UICC/AJCC tumour staging (Hutter, 1987), histological
grade (Bloom & Richardson, 1957), oestrogen and pro-
gesterone receptor (ER and PR) levels and the previously
described (Bryan et al., 1986) and validated (Alexander et al.,
1987) Melbourne Prognostic Index. The presence or absence
of lp abnormalities was compared with non-normally distri-
bution continuous data (e.g. tumour size) and ordered
categorical data (e.g. UICC stage) using the Mann-Whitney
U-Test, and with binary variables (e.g. node positivity) using
the Chi squared or Fisher Exact Probability Test as appro-
priate.
Since patients possessing cytogenetic data constituted a
small subgroup, they were compared with those lacking cyto-
genetic data for the above prognostic factors using the same
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The level of significance was set at P = 0.05 throughout.
Results
Cytogenetic abnormalities in tumours
The cytogenetic features of the 26 primary breast cancers are
summarised in Figures 1 and 2. Apparent discrepancies in
numbers between these figures result from the fact that indi-
vidual tumours may display multiple clonal abnormalities
affecting the same chromosome. Full karyotypic details are
to be found in Hainsworth et al. (1991).
Figure 1 shows that 25 tumours were informative for
chromosome #1 and these cases form the subject of this
paper. The clinico-pathological features of those with and
without cytogenetic data for chromosome #1 are shown in
Table I.
Abnormalities of the short arm of chromosome #1 were
found in 14 (56%) of the 25 primary breast tumours (Table
II). In four cases more than one abnormality of chromosome
lp was present in a single tumour. Translocations predomi-
nated, involving lp22 (n = 1), lp35 (n = 1) or lp36 (n = 10)
breakpoints (Figures 3 and 4). Because of limitations in the
chromosomal quality, only one of the translocation partners
was defined (case 104). Deletions were observed with break-
points at lpl2 (n = 1), lp22 (n = 2) and lp33 (n = 1), and
one inversion was identified with lp22-lp36 breakpoints.
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Figure 1 Non-random chromosome involvement in 26 primary
breast cancers. 'Uninformative' denotes insufficient metaphases
possessed good quality copies of a chromosome to enable charac-
terisation of that chromosome. , involved; X, normal;
=lI, uninformative.
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Figure 2 Breakdown of clonal chromosome abnormalities,
showing involvement of the p arm, q arm or centromere (e.g.
isochromosome or Robertsonian translocation) and chromosome
losses in fully characterised karyotypes. Where a chromosome has
p and q arm alterations, both are charted. Where one arm is
rearranged in two different ways, this is charted only once. ,
q arn; L], centromeric; , p arm; Ei, loss.
Table I Clinico-pathological features of breast cancer patients with
and without cytogenetic data for chromosome I (numbers oftumours
shown)
Cytogenetic data
Yes No
(n =25) (n = 119) Testa p
Age (years)
Median 52 61 M-W NS
Range 36-84 29-60
Tumours size (mm)
Median 25 25 M-W NS
Range 5-110 7-130
Nodal status
pNo 11 37 X2 NS
pN,,2 8 56 (1 d.f.)
pNX 6 26
UICC stage
I 5 19
II 12 51 M-W NS
III 4 21
IV 0 11
Not available 4 17
Histological type
Invasive ductal 18 104
Lobular 0 7 n/a
Medullary 1 0
Other 6 8
Histological grade
I 2 17
II 7 35 M-W NS
III 11 48
Not applicable 5 19
Hormone receptors'
ER- 9 35 X2 NS
ER+ 14 81 (I d.f.)
Not available 2 3
PR- 12 32 x2 0.035
PR+ 9 66 (I d.f.)
Not available 4 21
aM-W, Mann-Whitney U-test. x2, Chi squared test. n/a not app-
licable, d.f., degrees of freedom. bER, PR, cut-off, 10 fmol mg-'
cytosolic protein.
Table II Rearrangements of chromosome lp in primary breast
cancer
Case Rearrangement Breakpoint
906 der(l)t(1;?) p36
13 der(l)t(1;?) p35
15 inv(1) p22p36
23 der(I)t(1;?) p36
27 del(1) p22
i(lq)a centromeric
31 der(I)t(1;?) p36
40 der(I)t(1;?) p36
57 der(l)t(1;?) p36
73 der(l)t(1;?) p36
75 del(l) p22
der(I)t(1;?) p36
95 del(l) p33
der(l)t(1;?) p36
96 der(1)t(l;?) p36
104 der(l)t(1;7) p22
156 del(1) p12
der(1)t(1;?) p36
'Isomeric lq implying deletion of lp.
Clinico-pathological associations
Amongst patients with tumour karyotypes, the presence of
chromosome lp rearrangements was significantly associated
with ER negativity, high histological grade and high Mel-
bourne Prognostic NEPA and SEPA Scores, all signifying an
unfavourable prognosis (Table III).
The NEPA and SEPA scores are partly based on ER and
thus three of the four significant factors are interdependent.
However, in the absence of follow-up data the Melbourne
*Indicating sufficient metaphases possessed good quality copies of
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Figure 3 One of 11 karyotypes from case 73, with count of44 chromosomes, demonstrating der(l)t(l;?)(p36;?) (arrow). The other
der(l)t(l;?)(p36;?) is a single cell abnormality. Other clonal abnormalities present in this metaphase are der(1 l)t(l1;?)(q23;?) and an
undefined marker chromosome.
Figure 4 One of six karyotypes from case 104, with count of 58 chromosomes, demonstrating der(l)t(1;7)(p22;q11) (arrow).
Numerous other chromosomal abnormalities are present, of which the following were clonal: der(l)t(l;?)(q32;?), der(3)t(3;?)(?q25;?),
der(7)t(7;?)(q35;?), der(II)t(ll;?)(pl5;?)t(11;?)(q25;?), der(l2)t(12;?)(pl3;?), der(l6)t(16;?)(pl3;?) and der(l9)t(19;?)(ql3;?). The two
remaining #1 chromosomes have non-clonal abnormalities.134 P.J. HAINSWORTH et al.
TableIII Prognostic associationsofchromosome Ipstructural abnor-
malities (n = 25)
Chromosome Ip alteration
p
Yes (n = 14) No (n = 11) Testa (2-tailed)
Age (years)
Median 57 52 M-W NS
Range 36-84 37-72
Tumour size (mm)
Median 26 20 M-W NS
Range 10-55 5-110
Nodal status
pNo 5 6 x2 NS
pN,,2 6 2 (1 d.f.)
pN% 3 3
UICC stage
I 2 3
II 8 4 M-W NS
III 2 2
IV 0 0
Not available 2 2
Histological type
Invasive ductal 11 6
Medullary 1 0 n/a
Other 2 5
Histological grade
I 0 2
II 3 4 M-W 0.019
III 9 2
Not applicable 2 3
Hormone receptors
ER- 8 1 Exact 0.028c
ER+ 4 10
Not available 2 0
PR- 7 5 Exact NS
PR+ 4 5
Not available 3 10
Prognostic Indexd
NEPA - mean rank 12.45 6.63 M-W 0.020
SEPA - mean rank 15.12 9.41 M-W 0.037
IM-W, Mann-Whitney U-test. x2, Chi squared test (d.f., degrees of
freedom). n/a not applicable. Exact, Fisher exact probability test. bER,
PRcut-off, 10 fmol mg- I cytosolicprotein. cAnalysisusingabsolute ER
levelandMann-Whitney U-testdidnotreachsignificance. dNEPA = N-
+E+P+A [N =0ifnonodesinvolved, 13 if1-3 nodesinvolvedand 31
if >3 nodes involved; E= 15 if ER<lOfmolmg-, 0 otherwise;
P = 12.5 ifPR < 10 fmol mg-', 0 otherwise; A = number ofyears over
65]. SEPA = S+E + P + A, [S = 25iftumoursize >4 cm, 0otherwise;
E= 17 if ER<10 fmol mg-', 0 otherwise; P=23 if
PR< 10 fmol mg- , 0 otherwise; A = number of years over 65].
Prognostic Index has been shown to be the best available
indicator of outcome (Alexander et al., 1987). Analysis of the
other component variables of the NEPA and SEPA scores,
namely nodal status, tumour size, PR status and age,
revealed no significant associations with the presence of
chromosome Ip changes.
With the exception of one lobular tumour (case 104),
tumours with Ip abnormalities were all invasive ductal car-
cinomas.
In the comparison of those with and without chromosome
#1 data, those informative for chromosome #1 were more
likely to be PR negative (Table I). For all other clinico-
pathological factors assessed, those with chromosome #1
data exhibited no significant differences when contrasted with
the rest of the study group.
Discussion
At a cytogenetic level, little attempt has previously been
made to correlate chromosomal abnormalities in breast
cancer with clinical behaviour, no doubt because of the
enormous technical difficulties experienced in producing
analysable metaphases from breast tissue (Pathak, 1979;
Limon et al., 1986; Sandberg et al., 1988) and the marked
complexity and heterogeneity of karyotypic data obtained
(Rodgers et al., 1984; Hill et al., 1987; Gebhart et al., 1986;
Hainsworth et al., 1991).
At a molecular level, the prognostic associations for loss of
heterozygosity at some loci have been sought. Deletion
affecting the Harvey-ras locus (lipl5) has been linked with
poor prognosis (Theillet et al., 1986; Mackay et al., 1988).
Genuardi et al. (1989) reported that distal deletion of a
chromosome lp36 locus was more common in those with
early age of diagnosis, strong family history and multifocal
disease than in patients with none of the characteristics of
hereditary tumours (Genuardi et al., 1989). However, no
associations with standard staging and prognostic factors
were observed.
The data presented here show that chromosome lp rear-
rangements, predominantly distal translocations, were cyto-
genetically recognised in 14 (56%) of 25 primary breast
cancers. A preponderance of distal lp changes has not been
noticed by other authors. Mitchel and Santibanez-Koref
(1990) report involvement of chromosome lpl3 breakpoints
in 6/14 of their own breast cancers and in 17/99 specimens
(56 tumour biopsies and 43 pleural effusions) from the Uni-
versity of Lund computerised Cancer Chromosome Registry.
The assocation of chromosome lp abnormalities with four
of the prognostic factors studied suggests that rearrangement
at this site may correlate with tumour progression. In this
context it should be noted that chromosome #1 alterations
are frequently observed in both solid and haematological
malignancies (Heim & Mitelman, 1987). Teleologically, this
suggests a broad role for chromosome #1 abnormalities in
carcinogenesis, not confined to breast cancer.
In this study there were proportionately far more trans-
locations than deletions of chromosome lp. Based on these
results, it would be highly speculative to propose a specific
genetic mechanism operating at chromosome #1 which
could be implicated in tumour progression. These findings
are however in keeping with the occurrence ofallelic deletion
at the D1Z2 locus (mapping to chromosome lp36) in 41% of
37 informative tumours (Genuardi et al., 1989). The latter is
consistent with the notion that a suppressor gene near the
D1Z2 locus may be implicated in the pathogenesis of ductal
breast cancer.
The limitations of this analysis are recognised.
Chromosome #1 data was only available for 25 tumours.
These obviously represent a highly selected subgroups of the
patients treated during this period although comparison with
those lacking karyotypes suggested little bias. It is also con-
ceivable that the occurrence of lp abnormalities merely
represents an increase in genetic instability which happens to
be associated with features of poor prognosis. However the
frequency with which the distal portion of the p arm is
singled out indicates that some sort of selective process is at
work conveying an advantage to clones possessing distal lp
rearrangements.
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